Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 19, 2013
Pharmacy Choice - News - Over-the-Counter Drugs - May 19, 2013

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 24 of 24     Go To Page:

5/19/13 - Review: Cover Story: Does the Happy Pill help artists?: 'I felt as if I was walking through this grey world, with all the joy stripped out': More than 40 million people globally take an SSRI antidepressant, among them many writers and musicians. But
Twenty-five years after pharmaceutical giant Eli Lilly unleashed Prozac on the red-braced 80 s, SSRIs are still the world's most popular antidepressants. They are swallowed by more than 40 million people, from Beijing to Beirut, knitting a web of happiness from New York to New Caledonia. Like the Soma of Aldous Huxley's Brave New World, Prozac was
5/18/13 - Number One Calamine Lotion Caladryl Awards Hispanic Marketing Duties to XL Alliance
By a News Reporter-Staff News Editor at Marketing Weekly News Valeant Consumer Products, a division of Valeant Pharmaceuticals North America LLC, multinational and specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products, has recognized the size and growth of the U.S. Caladryl is a familiar
5/17/13 - City Invites Residents To Safely Get Rid Old, Unwanted Medicines, Drugs [The Hartford Courant]
May 17 NEW BRITAIN Residents with unwanted or expired prescription and non-prescription drugs are invited to drop them off at the senior center on May 17. New Britain Youth& Family Services/Community Services Department, along with the health department, the police department, the senior center and the Substance Abuse Action Council of Central
5/17/13 - Deborah Autor, FDA's Deputy Commissioner for Global Regulatory Operations and Policy, to Join Mylan
By a News Reporter-Staff News Editor at Health& Medicine Week Mylan Inc. announced that it has appointed Deborah M. Autor as senior vice president, Strategic Global Quality and Regulatory Policy. Autor joins Mylan from the U.S. Food and Drug Administration, where she served for 11 years, most recently as deputy commissioner for Global Regulatory
5/17/13 - Police, groups battle area's meth threat [The Tribune-Democrat, Johnstown, Pa.]
May 17 MEYERSDALE After three drug arrests in connection with two Meyersdale- area methamphetamine labs, Somerset County authorities said they hope a strong message is being sent to drug manufacturers and dealers operating in the region. State police, in conjunction with the Somerset Single County Authority for Drug and Alcohol and Somerset Cou
5/16/13 - Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Bar Code Label Requirement for...
All comments should be identified with the OMB control number 0910-0537. Also include the FDA docket number found in brackets in the heading of this document. FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville, MD 20850, 301-796-7726,...
5/16/13 - City Invites Residents To Safely Get Rid Old, Unwanted Medicines, Drugs [The Hartford Courant]
May 16 NEW BRITAIN Residents with unwanted or expired prescription and non-prescription drugs are invited to drop them off at the senior center on May 17. New Britain Youth& Family Services/Community Services Department, along with the health department, the police department, the senior center and the Substance Abuse Action Council of Central
5/16/13 - FDA Approves Over-The-Counter Availability of Plan B One-Step levonorgestrel tablet 1.5 mg for Consumers 15 and Over
By a News Reporter-Staff News Editor at Women's Health Weekly Teva Women's Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved the emergency contraceptive Plan B One-Step tablet 1.5 mg for over-the-counter sale to consumers 15 years of age and older in
5/16/13 - Helsinn and Vifor Pharma Sign Licensing and Distribution Agreement for Netupitant-Palonosetron Fixed Dose Combination
Helsinn Healthcare SA and Vifor Pharma, announced that the companies have entered into an exclusive license and distribution agreement for netupitant-palonosetron fixed dose combination, a Helsinn product currently in the development stage for the treatment of chemotherapy-induced nausea and vomiting. Under the agreement, Vifor Pharma will have...
5/16/13 - Personal Injury Law Firm Releases Tylenol Infographic Detailing Alleged Side Effects Linked to the Drug
It is manufactured by McNeil Consumer Healthcare, which is now a subsidiary of Johnson& Johnson. The FDA has issued warnings that the acetaminophen class of drugs may cause liver damage in some cases and the agency has even taken steps to limit the dosage of these drugs. In January 2011, the FDA limited acetaminophen products to 325 milligrams per
5/15/13 - ALR TECHNOLOGIES INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results. As used in this quarterly report, the terms "we", "us", "our", the "Company" and "ALRT" mean ALR Technologies Inc, unless otherwise indicated. ALR T
5/15/13 - AOXING PHARMACEUTICAL COMPANY, INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Quarterly Report on Form 10- Q contains certain "forward-looking statements" within the meaning of Section 27 A of the Securities Act of 1933, as amended, and Section 21 E of the Securities Exchange Act of 1934, as amended, as well as information relating to Aoxing Pharmaceutical Company, Inc. that is based on management's exercise of business
5/15/13 - BIO-PATH HOLDINGS INC - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Bio-Path Holdings, Inc. is a development stage company with its lead cancer drug candidate, Liposomal Grb-2, currently in clinical trials. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company's current delivery technology to improve further the effectivenes
5/15/13 - Cardium Presents First Quarter 2013 Financial Results And Reports On Recent Developments
Cardium Therapeutics today presented its financial results for the first quarter ended March 31, 2013, and reported on highlights and other recent developments including:. Including Academy Medical, there are currently over 60 sales representatives selling Excellagen. Excellagen awarded the American Podiatric Medical Association' s Seal of Approval
5/15/13 - MMRGLOBAL, INC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion of our financial condition and results of operations in conjunction with our financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10- Q and the description of our business appearing in our Annual Report on Form 10- K for the year ended December 31, 2012, filed with the
5/15/13 - Pain Medication OTC Manufacturing in Australia Industry Market Research Report Now Available from IBISWorld
The Pain Medication OTC Manufacturing industry manufactures pharmaceutical products that focus on pain relief and are available without a doctor's permission. According to IBISWorld industry analyst Craig Shulman, global pharmaceutical manufacturing has shifted production towards Asia, where labour is cheaper and the plants are larger, leading t
5/15/13 - PURAMED BIOSCIENCE INC. - 10-Q - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Forward-looking statements may also be made in the Company's other reports filed with or furnished to the SEC and in other documents. PuraMed BioScience, Inc. was incorporated in Minnesota on May 9, 2006, as a wholly-owned subsidiary of Wind Energy America, Inc. for the purpose of engaging in the business of developing and marketing non-prescrip
5/14/13 - BestSweet Changes Name to BestCo [Professional Services Close - Up]
BestCo announced that it is the new name for BestSweet, a manufacturer, developer and marketer of consumer healthcare products for retailers and marketers of over-the-counter drug products and dietary supplements. According to a release, BestCo has evolved to become a supplier of cough drops, throat drops, soft chews, coated chews and other...
5/14/13 - Health Q&A: FDA warns of migraine drug risk during pregnancy [The Sentinel, Carlisle, Pa.]
May 14 The Associated Press reported last week the Food and Drug Administration is advising pregnant women and women of child-bearing age to beware of medications that treat migraine headaches. The FDA said those medications, which includes Depakote and Depcaon, should not be taken by pregnant women because of the possible risk of birth defects a
5/14/13 - SKINVISIBLE INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Further information concerning our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC. We, through our wholly owned subsidiary Skinvisible Pharmaceuticals Inc., are a pharmaceutical research and development company that has developed and patented an...
5/14/13 - TRANZYME INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included in our Annual Report on Form 10- K, as well as the information relating to such audited financial statements contained under the heading "Management's Discussion and Analysis of
5/13/13 - Actavis' NDA for Progestin-Only Patch Accepted for Filing by FDA
Actavis, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing Actavis' New Drug Application for a progestin-only transdermal contraceptive patch for use by women to prevent pregnancy. Actavis' progestin-only patch is designed to provide continuous delivery of norethindrone to the systemic circulation during a...
5/13/13 - Prasco announces agreement with WellSpring for the Authorized Generic of DIBENZYLINE
By a News Reporter-Staff News Editor at Pharma Business Week- Prasco Laboratories announced it has signed an exclusive distribution and supply agreement with WellSpring Pharmaceutical Corp. for Phenoxybenzamine Hydrochloride Capsules, USP. As part of the agreement, Prasco, LLC is prepared to immediately market the authorized generic of DIBENZYLIN
5/13/13 - VIVUS Mails Letter to Stockholders Providing Business Update
MOUNTAIN VIEW, Calif., May 13, 2013 VIVUS, Inc. today mailed a letter to stockholders providing an update on the Company's recent progress. Over the past seven months since the launch of Qsymia, VIVUS has successfully built the commercial foundation for the medical obesity treatment category and the Qsymia brand. Just this month, the American Ass
Articles(s): 1 - 24 of 24     Go To Page:


© 2013 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Insulin Therapy in Type 2 Diabetes: Does Tight Glycemic Control Still Matter?
This lesson is supported by:
Texas A&M Health Science Center Coastal Bend Health Education Center

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415